Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation

[11] Vergouwen M.D., Casaubon L.K., Swartz R.H., Et al., Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator, Stroke, 42, pp. 1041-1045, (2011)

[12] Larrue V., von Kummer R.R., Muller A., Bluhmki E., Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II), Stroke, 32, pp. 438-441, (2001)

[13] Lees K.R., Bluhmki E., von Kummer R., Et al., Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials, Lancet, 375, pp. 1695-1703, (2010)

[14] Wahlgren N., Ahmed N., Davalos A., Et al., Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study, Lancet, 369, pp. 275-282, (2007)

[15] Albers G.W., Bates V.E., Clark W.M., Bell R., Verro P., Hamilton S.A., Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study, JAMA, 283, pp. 1145-1150, (2000)

[16] Rizos T., Herweh C., Jenetzky E., Et al., Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants, Stroke, 40, pp. 3547-3551, (2009)

[17] Janjua N., Alkawi A., Georgiadis A., Et al., Feasibility of IA thrombolysis for acute ischemic stroke among anticoagulated patients, Neurocrit Care, 7, pp. 152-155, (2007)

[18] Linfante I., Reddy A.S., Andreone V., Caplan L.R., Selim M., Hirsch J.A., Intra-arterial thrombolysis in patients treated with warfarin, Cerebrovasc Dis, 19, pp. 133-135, (2005)

[19] Nogueira R.G., Smith W.S., Safety and efficacy of endovascular thrombectomy in patients with abnormal hemostasis: pooled analysis of the MERCI and multi MERCI trials, Stroke, 40, pp. 516-522, (2009)

[20] Kidwell C.S., Saver J.L., Carneado J., Et al., Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis, Stroke, 33, pp. 717-724, (2002)

[11] Vergouwen M.D., Casaubon L.K., Swartz R.H., Et al., Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator, Stroke, 42, pp. 1041-1045, (2011)

[12] Larrue V., von Kummer R.R., Muller A., Bluhmki E., Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II), Stroke, 32, pp. 438-441, (2001)

[13] Lees K.R., Bluhmki E., von Kummer R., Et al., Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials, Lancet, 375, pp. 1695-1703, (2010)

[14] Wahlgren N., Ahmed N., Davalos A., Et al., Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study, Lancet, 369, pp. 275-282, (2007)

[15] Albers G.W., Bates V.E., Clark W.M., Bell R., Verro P., Hamilton S.A., Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study, JAMA, 283, pp. 1145-1150, (2000)

[16] Rizos T., Herweh C., Jenetzky E., Et al., Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants, Stroke, 40, pp. 3547-3551, (2009)

[17] Janjua N., Alkawi A., Georgiadis A., Et al., Feasibility of IA thrombolysis for acute ischemic stroke among anticoagulated patients, Neurocrit Care, 7, pp. 152-155, (2007)

[18] Linfante I., Reddy A.S., Andreone V., Caplan L.R., Selim M., Hirsch J.A., Intra-arterial thrombolysis in patients treated with warfarin, Cerebrovasc Dis, 19, pp. 133-135, (2005)

[19] Nogueira R.G., Smith W.S., Safety and efficacy of endovascular thrombectomy in patients with abnormal hemostasis: pooled analysis of the MERCI and multi MERCI trials, Stroke, 40, pp. 516-522, (2009)

[20] Kidwell C.S., Saver J.L., Carneado J., Et al., Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis, Stroke, 33, pp. 717-724, (2002)